RLMD
Relmada Therapeutics, Inc.
Healthcare · Biotechnology · NCM
$7.26
Close 2026-05-28
✗ NOT SCREENED

UNKNOWN MOAT
MODERATE
Data Confidence: 71%
Some financial metrics pending
Market Cap
$761.5M
Trailing P/E
Forward P/E
-17.71
Rev Growth
Profit Margin
0.0%
ROE
-25.6%
Analyst Target
$12.00
Recommendation
STRONG BUY
About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue RatioN/A
OverallINSUFFICIENT DATA
Score Ethical: 50.0
Score Valuation: 33.0
Score Quality: 21.2
Score Combined: 30.2

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation50.0
Quality12.5
Cash Flow0.0
Moat40.0
Balance Sheet100.0
Debt Purity50.0
Liquid Purity50.0
Rev Purity50.0
Compliance100.0
Tier: BRONZE · Score: 40.2 · Rank: #4223
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
-$33.7M
Price/Book
6.14
Analysts
5
Total Debt
$110.2K
Short Ratio
4.75
Short % Float
0.1%
Employees
17

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 30.2 (P14 — top 86.3% of scored tickers). Unknown Moat. Ethical FAIL. 5 analysts at None.
Price: $7.26 | Target: $12.80 (+76%)
Score
30
Moat
Unknown
Conviction
Standard
Upside
+76%
The Fundamentals
Profit Margin0.0%
ROE-25.6%
Forward P/E-17.7
Market Cap$761.5M
Position Sizing Scenarios
Stop: $6.17 (-15%) | Entry: $7.26
SharesCostProfit to TargetR:R
To Consensus ($12.80, 5 analysts)
10$72.60+$55.40 (76%)5.1R
50$363.00+$277.00 (76%)5.1R
100$726.00+$554.00 (76%)5.1R
Risk Factors
  • Elevated short interest (4.75 days to cover)
The Verdict
Relmada Therapeutics, Inc. holds a unknown competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

C
Quant Score
51.0
Risk Grade
Layers
7
Quality: HIGH_VOL
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-9.3%
worst expected daily loss, 19 in 20 days
CVaR 95%
-20.6%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
0.27
above 1.0 is good
Max Drawdown
-94.2%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
55
Liquidity Grade
MODERATE
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
ABOVE_200
Bollinger Position
LOWER_HALF
Beta
Relative Volume
0.7x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
PURR0.385
BETA0.285
OJIPY0.256
HLTHQ0.229
ZIG.L0.229
Inverse Correlated
TickerCorrelation
PRN.L-0.215
DUBAIRESI.AE-0.184
VFS-0.179
ALEC.AE-0.168
OSOUL.KW-0.159
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Monday
Worst Day
Wednesday
Best Month
May
Worst Month
Dec
Fri-Mon Effect
-0.8028359571330848
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
+0.1%
3M Return
+57.6%
6M Return
+68.6%
12M Return
+995.2%
Momentum Rank
#66
Momentum Signal
STRONG_UP

Get our daily market read free. Join thousands of traders.

Free Explorer Access